ADMA Biologics (Nasdaq: ADMA) will report its second quarter 2026 financial results on August 5, 2026, after U.S. markets close. Management will host a live conference call and audio webcast at 4:30 p.m. ET to discuss the results and provide company updates.
Participants must register in advance to receive dial-in details and a unique PIN. A replay will be available under “Events & Webcasts” in the investor section of ADMA’s website.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
Director Jerrold B. Grossman's recent filings recorded 31,400 shares bought and no shares sold. Agai...
Analysis
Director Jerrold B. Grossman's recent filings recorded 31,400 shares bought and no shares sold. Against that insider context, this announcement only sets the reporting date; prior earnings-date reactions of -2.75% and +0.25% are the relevant risk comparison.
Key Figures
Reporting Date:August 5, 2026Conference Call Time:4:30 p.m. ETRecommended Early Arrival:10 minutes+1 more
Conference Call Scheduled for August 5, 2026, at 4:30 p.m. ET
RAMSEY, N.J. and BOCA RATON, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report second quarter 2026 financial results on August 5, 2026, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.
To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and unique PIN. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here. An archived replay of the event will be available located under “Events & Webcasts” in the investor section of the Company’s website at https://ir.admabiologics.com/events-webcasts.
ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Additionally, ADMA is developing SG-001, a pre-clinical, investigative hyperimmune globulin targeting S. pneumonia. ADMA manufactures its immune globulin products and product candidates at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides its blood plasma for the manufacture of its products and product candidates. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit www.admabiologics.com.
When will ADMA (Nasdaq: ADMA) report its Q2 2026 financial results?
ADMA will report its second quarter 2026 financial results on August 5, 2026, after U.S. markets close. According to ADMA Biologics, the release will be followed by a management conference call and webcast at 4:30 p.m. ET that same day.
What time is ADMA Biologics’ Q2 2026 earnings conference call on August 5, 2026?
ADMA Biologics’ Q2 2026 earnings conference call is scheduled for 4:30 p.m. ET on August 5, 2026. According to ADMA, the call will follow the results release and include financial discussion and broader company updates for investors and analysts.
How can investors access the ADMA (ADMA) Q2 2026 earnings call and webcast?
Investors must register online to receive dial-in numbers and a unique PIN for ADMA’s Q2 2026 call. According to ADMA Biologics, participants may also listen via a live audio webcast, with links provided in the investor section of the company’s website.
Will a replay of ADMA Biologics’ Q2 2026 earnings webcast be available to shareholders?
Yes, a replay of ADMA Biologics’ Q2 2026 earnings event will be available. According to ADMA, the archived webcast can be accessed under “Events & Webcasts” in the investor section of its website after the live call concludes.
Do participants need to register in advance for ADMA’s August 5, 2026 Q2 2026 earnings call?
Yes, participants are required to register in advance to access ADMA’s Q2 2026 earnings call. According to ADMA Biologics, registration provides the necessary dial-in numbers and a unique PIN, and investors are encouraged to join about 10 minutes before the start.
